Kalvista Pharmaceuticals Ownership
| KALV Stock | USD 10.15 0.83 8.91% |
Shares in Circulation | First Issued 2015-06-30 | Previous Quarter 37 M | Current Value 46 M | Avarage Shares Outstanding 17.3 M | Quarterly Volatility 11.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Kalvista |
Kalvista Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of Kalvista Pharmaceuticals was now reported as 4.01. The company recorded a loss per share of 3.57. Kalvista Pharmaceuticals last dividend was issued on the 22nd of November 2016. The entity had 1:14 split on the 22nd of November 2016. KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Kalvista Pharmaceuticals contact Thomas MBA at 857 999 0075 or learn more at https://www.kalvista.com.Besides selling stocks to institutional investors, Kalvista Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Kalvista Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Kalvista Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Kalvista Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Kalvista Pharmaceuticals Insider Trades History
Only 1.34% of Kalvista Pharmaceuticals are currently held by insiders. Unlike Kalvista Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Kalvista Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Kalvista Pharmaceuticals' insider trades
Kalvista Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kalvista Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kalvista Pharmaceuticals backward and forwards among themselves. Kalvista Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kalvista Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Emerald Advisers, Llc | 2024-09-30 | 836 K | Geode Capital Management, Llc | 2024-09-30 | 831 K | State Street Corp | 2024-06-30 | 756.4 K | Dafna Capital Management Llc | 2024-09-30 | 723.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 677.2 K | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 651 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 607 K | Silverarc Capital Management, Llc | 2024-06-30 | 560.9 K | Saturn V Capital Management Llc | 2024-09-30 | 556.5 K | Vr Adviser, Llc | 2024-09-30 | 6.2 M | Tang Capital Management Llc | 2024-09-30 | 4.3 M |
Kalvista Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kalvista Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kalvista Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kalvista Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kalvista Pharmaceuticals Outstanding Bonds
Kalvista Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kalvista Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kalvista bonds can be classified according to their maturity, which is the date when Kalvista Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Kalvista Pharmaceuticals Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 7th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.